In Case You Missed It: R&D refunds for drug developers and a major uranium merger

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar.

Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.

ICYMI Leader Board

Code Company Price % Today Market Cap NYR Nyrada Inc. 0.026 30% $3,120,174 92E 92Energy 0.455 25% $38,826,912 EYE Nova EYE Medical Ltd 0.135 17% $21,922,323 HCT Holista CollTech Ltd 0.014 17% $3,345,601 PNN Power Minerals Ltd 0.23 15% $17,468,462 OSL Oncosil Medical 0.009 13% $15,796,329 NAG Nagambie Resources 0.032 10% $16,870,063 XAM Xanadu Mines Ltd 0.054 10% $83,340,213 IXC Invex Ther 0.07 10% $4,787,300 BAT Battery Minerals Ltd 0.038 9% $4,186,157 BMR Ballymore Resources 0.14 8% $20,976,377 CTE Cryosite Limited 0.6 7% $27,333,355 WCG Webcentral Ltd 0.255 6% $80,172,295 LM8 Lunnonmetalslimited 0.69 6% $141,086,557 FBM Future Battery 0.074 6% $37,362,919 RKT Rocketdna Ltd. 0.0095 6% $4,805,034 E33 East 33 Limited. 0.02 5% $10,204,685 TLM Talisman Mining 0.21 5% $37,664,070 NRZ Neurizer Ltd 0.022 5% $28,496,690 DSK Dusk Group 0.99 5% $58,843,132

WordPress Tables Plugin

Cardiovascular and neurological drug development company Nyrada (ASX:NYR) has received a A$3,541,731 cash rebate from the Australian Federal Government’s Research & Development (R&D) tax incentive program.

92 Energy (ASX:92E) is merging with TSX-listed ATHA Energy at an implied 78% premium to the last 92E share price, and 70% premium to the 30-day VWAP.

Nova Eye Medical (ASX:EYE) says five MACs (Medicare Administrative Contractors) have deferred the proposed USA reimbursement changes from 23 December 2023, to January 29, 2024 – which is a positive outcome for the near-term sales of the company’s iTrack portfolio of canaloplasty devices, which continue to be strong since the US launch of iTrack Advance in May.

Holista CollTech (ASX:HCT) says the judge overseeing the Federal Court stoush between the company and the Australian Securities and Investments Commission pulled the pin on proceedings a day earlier than expected. No decision has been announced.

And pancreatic cancer medical device company OncoSil Medical (ASX:OSL) says the first initial commercial treatments involving the OncoSil device in Greece have just commenced at a renowned hospital in Athens.